RayzeBio is the lead sponsor of 5 current clinical trials in our USA register. 3 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are RYZ101, Atezolizumab and Carboplatin. The most-studied condition is GEP-NET.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161 · Hepatocellular Carcinoma (HCC)
|
Phase 1/2 | Recruiting | 2025-09 | USA |
|
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05477576 · ClinicalTrials.gov ↗ · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease
|
Phase 3 | Recruiting | 2022-03 | USA |
|
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132 · ClinicalTrials.gov ↗ · GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease
|
Phase 1 | Recruiting | 2025-12 | USA |
|
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
Drug: RYZ101 |
Phase 1/2 | Active, closed | 2024-07 | USA |
|
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage
|
Phase 1 | Active, closed | 2022-10 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 3 |
A trial with sites in more than one country appears in each of those registers.
RayzeBio is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 7 drugs and biologicals as interventions. The most frequent are RYZ101 (3), Atezolizumab (1), Carboplatin (1), Etoposide (1) and Everolimus (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.